Gene Signal is run by an experienced and multi-disciplinary management team of leading angiogenesis scientists and established professionals from the pharmaceutical and medical sectors. The members of the management are also the private share holders of the company. They are dedicated and committed to the success of Gene Signal. They ensure Gene Signal scientific know-how, senior operational, financial and marketing skills, expertise in new product development and product pipeline validation as well as senior contacts with global pharmaceutical groups and regulatory bodies.
Eric Viaud, Chief Executive Officer
Eric is one of the company’s founders. He is the current CEO of the company. His leadership has successfully brought the company from the drug discovery phase to the current clinical development phases. Eric has a demonstrated track record as a biotech entrepreneur, having successfully overseen and led the development of several Biotech start-up ventures. He is currently an Advisor and Board Member of various biotech companies in Europe. Eric began his career in the Pharmaceuticals Industry and then later moved to Medical Devices. He has held Senior Management positions in the field of sales & marketing, licensing, strategic alliances and medical and R&D. He also has extensive experience in the regulatory & reimbursement fields. Eric holds a Master Degree in Clinical Psychopathology from the University of Bordeaux (France).
Salman Al-Mahmood, Chief Scientific Officer
Salman is the company’s principal founder and an established scientific leader whose early ground breaking work in angiogenesis earned him well recognized honours and awards from the French Government. Salman has successfully led Gene Signal’s discovery team and his work has allowed the company to become owner of one of the world’s largest collection of patents in the field of angiogenesis. Prior to Gene Signal Salman led several scientific teams in the field of angiogenesis, oncology and cell-signalling. He was a scientist and Head of the Biochemistry team in the NADER oncology laboratory at Cochin Hospital, Paris and Head of the Radioactive Labeling team at the Center for Nuclear Medicine, Faculty of Medicine, University of Nancy. Salman holds a PhD in Microbial Biochemistry from the University of Nancy (France), a Master of Science in Applied Biology for Nutrition and BioIndustry from the University of Nancy, France.
Dr. Eric Thorin, Chief Development Officer
Eric is one of the company’s founders. Eric directs the Company’s drug development work and has successfully steered Gene Signal’s leading products through several drug development phases. Eric is a recognized international expert in the field of vascular mechanisms and CVD. He is Associate Professor of Surgery of the Faculty of Medicine of the University of Montreal and a senior researcher at the Montreal Heart Institute. He was formerly Head of Cardiovascular Pharmacology of Actelion Pharmaceuticals (Basel, Switzerland). Eric has received the 1996 Young Investigator Award from the International Society of Hypertension, the 1997 Jonathan Ballon Award of the Quebec Heart & Stroke Foundation and the 1999 MacDonald Award of the Canadian Heart & Stroke Foundation.
Marta Gehring, BD&L and Chief Marketing Officer
Marta joins Gene Signal as Chief Marketing Officer focusing her efforts on late stage projects. She guides all aspects of Gene Signal’s medical marketing strategy and is currently successfully steering Ophthalmic applications to bring Gene Signal’s first products to market. Marta brings experience from the Biotechnology and Medical Device industries and has held senior positions in strategic planning, operational marketing and sales management. From the upstream perspective, Marta has a successful track record of collaborating with clinical departments to devise and execute strategic clinical trials, as well as in concluding landmark publications in key journals on trial results and treatment guidelines.
Antoine Ferry, Chief Medical Officer
Antoine is Gene Signal’s Chief Medical Officer responsible for the company’s clinical development strategy. He has played a leading role in the new product development process through successful clinical and regulatory management. Antoine is a biotech entrepreneur with a proven track record in the field of biotechnology. His outstanding work was recognized in 2001 by a National Master Prize (ANVAR 2001). Antoine is also the Board Member of several biotechnology firms. Antoine brings Gene Signal a vast experience in the fields of business development, pharmacology and regulatory. He holds Masters in Clinical Pharmacology, Experimental Pharmacology and Medical Statistics and has over 15 international publications to his name.
John Dickinson, Chief Corporate Development Officer
John joined Gene Signal in 2009 and is currently the company’s Chief Corporate Development Officer. He provides guidance on the full range of financial matters as well as business development notably with respect to business partnerships including licensing out. John, with twenty seven years experience as a senior financial executive with international companies, spent eleven years as VP and CFO of Galderma, one of the world’s leading and most successful dermatology pharmaceutical companies He also held various financially related positions in Clintec France, a pharmaceutical company specializing in clinical nutrition, Spie Batignolles as VP and CFO of the engineering and general contracting division, and the El Paso group of companies a natural gas transmission company based in the USA with operations in Algeria. Previously, John spent ten years in public accounting with major firms in the UK and France. Gene Signal will benefit from John’s solid background in the pharmaceutical industry with a special emphasis in high growth businesses embracing business development, product and company acquisitions, change management during times of industries undergoing fundamental changes as well all aspects of the finance, audit, accounting, tax, legal, information systems and administrative functions of operating units. John is a member of the Institute of Chartered Accountants in England and Wales. He is also currently a jury member of the Cartier Women Initiative Awards for the promotion of female entrepreneurs.